Aribio to Officially Attend 2026 JP Morgan Healthcare Conference... Accelerating Global Big Deal Talks for AR1001

Aribio announced on January 8 that it will officially participate in the "2026 JP Morgan Healthcare Conference," which opens on January 12, 2026, local time in the United States. The company plans to accelerate partnership discussions regarding licensing agreements and investment attraction for its oral Alzheimer's treatment candidate AR1001, targeting major global markets such as the United States and Europe.

Now in its 44th year, the JP Morgan Healthcare Conference is the world's largest investor event representing the global pharmaceutical and biotech industry. The event will be held in San Francisco, California, from January 12 to 15.

Recently, Aribio signed an exclusive licensing agreement for AR1001 worth a total of 630 billion won with China's Newco Pharma and Fuxing Pharmaceutical, covering 10 ASEAN countries, thereby solidifying its commercialization strategy in Asia. Including this deal, the cumulative global contract value for AR1001 has reached approximately 2.99 trillion won. The company intends to use this conference as an opportunity to further accelerate strategic partnership discussions targeting key markets such as North America, Europe, and Japan.

Fred Kim, Head of Aribio USA, and Tanya Xi, Director of Business Development (BD), will attend the event to hold partnering meetings with global pharmaceutical companies and investors. The meetings will focus on: ▲ licensing agreements for major markets including the United States, Europe, and Japan; ▲ investment attraction from global pharmaceutical companies and financial investors (FIs); ▲ strategies for follow-up pipelines and combination/indication expansion for AR1001; and ▲ development of digital therapeutics.

Aribio will also pursue discussions on collaboration for its cognitive improvement medical device "HERZION." HERZION demonstrated safety and potential for cognitive function improvement in exploratory clinical trials targeting patients with mild cognitive impairment (MCI) and early-stage dementia. The company plans to expand the scope of collaboration as part of a combined treatment and integrated solution strategy with AR1001 in the future.

Kim stated, "Aribio USA has served as a key base for global clinical operations, business development, and licensing-out (LO) negotiations focused on North America and Europe. Through this conference, we will further materialize global big deal discussions for AR1001 and concentrate our efforts on achieving tangible results."

He added, "With the recent release of a special report by GlobalData in the United Kingdom and the signing of a major license agreement in the ASEAN region, the commercial value and global competitiveness of AR1001 are being further highlighted."

Meanwhile, Aribio is pursuing a merger with Kosdaq-listed company Solux, with the scheduled merger date set for March 27.